Economic burden of hospital admissions for adverse drug reactions in France: The IATROSTAT‐ECO study
Aims Hospitalizations for adverse drug reactions (ADR‐HA) have increased over the last decade, but the impact of ADR‐HA has rarely been evaluated. The aim of this study was to estimate the economic burden of ADR‐HA in France. Methods A partial economic evaluation from the viewpoint of French public...
Uloženo v:
| Vydáno v: | British journal of clinical pharmacology Ročník 91; číslo 2; s. 439 - 450 |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
John Wiley and Sons Inc
01.02.2025
|
| Témata: | |
| ISSN: | 0306-5251, 1365-2125, 1365-2125 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Aims
Hospitalizations for adverse drug reactions (ADR‐HA) have increased over the last decade, but the impact of ADR‐HA has rarely been evaluated. The aim of this study was to estimate the economic burden of ADR‐HA in France.
Methods
A partial economic evaluation from the viewpoint of French public health insurance was performed, based on a previous pharmacovigilance study (IATROSTAT) performed in 2018 in public hospital medical units. The cost included direct medical costs, collected retrospectively, from the French hospital discharge database. The economic burden was estimated by calculating the total cost per ADR‐HA patient (cost of hospital stays, additional daily cost of specific stays, such as in a resuscitation, intensive care or continuous surveillance unit, drug products and medical devices in addition to Healthcare Resource Group‐based tariffs, and specific outpatient consultations and other clinical and technical medical procedures, over 3 months as from the first day of ADR‐HA). The robustness of the results was assessed using a one‐way deterministic sensitivity analysis of cost factors applying tariffs from 2023 instead of 2018.
Results
According to the 2018 tariffs (vs. 2023), the mean total cost per patient with ADR‐HA was estimated at €5208 ± €3719 (vs. €5974 ± €4232) ranging from €514 to €23 355 (vs. €618 to €27 380). The total cost for 196 patients with ADR‐HA admitted to a sample of French public hospitals was estimated at €1 020 549 (vs. €1 170 960). It could be estimated at €1.3 billion at the national level.
Conclusions
In addition to the increase in the number of expensive drugs, the ageing population and polypharmacy, the economic impact of serious ADR‐HA weighs heavily on healthcare spending. |
|---|---|
| AbstractList | Hospitalizations for adverse drug reactions (ADR-HA) have increased over the last decade, but the impact of ADR-HA has rarely been evaluated. The aim of this study was to estimate the economic burden of ADR-HA in France.AIMSHospitalizations for adverse drug reactions (ADR-HA) have increased over the last decade, but the impact of ADR-HA has rarely been evaluated. The aim of this study was to estimate the economic burden of ADR-HA in France.A partial economic evaluation from the viewpoint of French public health insurance was performed, based on a previous pharmacovigilance study (IATROSTAT) performed in 2018 in public hospital medical units. The cost included direct medical costs, collected retrospectively, from the French hospital discharge database. The economic burden was estimated by calculating the total cost per ADR-HA patient (cost of hospital stays, additional daily cost of specific stays, such as in a resuscitation, intensive care or continuous surveillance unit, drug products and medical devices in addition to Healthcare Resource Group-based tariffs, and specific outpatient consultations and other clinical and technical medical procedures, over 3 months as from the first day of ADR-HA). The robustness of the results was assessed using a one-way deterministic sensitivity analysis of cost factors applying tariffs from 2023 instead of 2018.METHODSA partial economic evaluation from the viewpoint of French public health insurance was performed, based on a previous pharmacovigilance study (IATROSTAT) performed in 2018 in public hospital medical units. The cost included direct medical costs, collected retrospectively, from the French hospital discharge database. The economic burden was estimated by calculating the total cost per ADR-HA patient (cost of hospital stays, additional daily cost of specific stays, such as in a resuscitation, intensive care or continuous surveillance unit, drug products and medical devices in addition to Healthcare Resource Group-based tariffs, and specific outpatient consultations and other clinical and technical medical procedures, over 3 months as from the first day of ADR-HA). The robustness of the results was assessed using a one-way deterministic sensitivity analysis of cost factors applying tariffs from 2023 instead of 2018.According to the 2018 tariffs (vs. 2023), the mean total cost per patient with ADR-HA was estimated at €5208 ± €3719 (vs. €5974 ± €4232) ranging from €514 to €23 355 (vs. €618 to €27 380). The total cost for 196 patients with ADR-HA admitted to a sample of French public hospitals was estimated at €1 020 549 (vs. €1 170 960). It could be estimated at €1.3 billion at the national level.RESULTSAccording to the 2018 tariffs (vs. 2023), the mean total cost per patient with ADR-HA was estimated at €5208 ± €3719 (vs. €5974 ± €4232) ranging from €514 to €23 355 (vs. €618 to €27 380). The total cost for 196 patients with ADR-HA admitted to a sample of French public hospitals was estimated at €1 020 549 (vs. €1 170 960). It could be estimated at €1.3 billion at the national level.In addition to the increase in the number of expensive drugs, the ageing population and polypharmacy, the economic impact of serious ADR-HA weighs heavily on healthcare spending.CONCLUSIONSIn addition to the increase in the number of expensive drugs, the ageing population and polypharmacy, the economic impact of serious ADR-HA weighs heavily on healthcare spending. Aims Hospitalizations for adverse drug reactions (ADR‐HA) have increased over the last decade, but the impact of ADR‐HA has rarely been evaluated. The aim of this study was to estimate the economic burden of ADR‐HA in France. Methods A partial economic evaluation from the viewpoint of French public health insurance was performed, based on a previous pharmacovigilance study (IATROSTAT) performed in 2018 in public hospital medical units. The cost included direct medical costs, collected retrospectively, from the French hospital discharge database. The economic burden was estimated by calculating the total cost per ADR‐HA patient (cost of hospital stays, additional daily cost of specific stays, such as in a resuscitation, intensive care or continuous surveillance unit, drug products and medical devices in addition to Healthcare Resource Group‐based tariffs, and specific outpatient consultations and other clinical and technical medical procedures, over 3 months as from the first day of ADR‐HA). The robustness of the results was assessed using a one‐way deterministic sensitivity analysis of cost factors applying tariffs from 2023 instead of 2018. Results According to the 2018 tariffs (vs. 2023), the mean total cost per patient with ADR‐HA was estimated at €5208 ± €3719 (vs. €5974 ± €4232) ranging from €514 to €23 355 (vs. €618 to €27 380). The total cost for 196 patients with ADR‐HA admitted to a sample of French public hospitals was estimated at €1 020 549 (vs. €1 170 960). It could be estimated at €1.3 billion at the national level. Conclusions In addition to the increase in the number of expensive drugs, the ageing population and polypharmacy, the economic impact of serious ADR‐HA weighs heavily on healthcare spending. Hospitalizations for adverse drug reactions (ADR-HA) have increased over the last decade, but the impact of ADR-HA has rarely been evaluated. The aim of this study was to estimate the economic burden of ADR-HA in France. A partial economic evaluation from the viewpoint of French public health insurance was performed, based on a previous pharmacovigilance study (IATROSTAT) performed in 2018 in public hospital medical units. The cost included direct medical costs, collected retrospectively, from the French hospital discharge database. The economic burden was estimated by calculating the total cost per ADR-HA patient (cost of hospital stays, additional daily cost of specific stays, such as in a resuscitation, intensive care or continuous surveillance unit, drug products and medical devices in addition to Healthcare Resource Group-based tariffs, and specific outpatient consultations and other clinical and technical medical procedures, over 3 months as from the first day of ADR-HA). The robustness of the results was assessed using a one-way deterministic sensitivity analysis of cost factors applying tariffs from 2023 instead of 2018. According to the 2018 tariffs (vs. 2023), the mean total cost per patient with ADR-HA was estimated at €5208 ± €3719 (vs. €5974 ± €4232) ranging from €514 to €23 355 (vs. €618 to €27 380). The total cost for 196 patients with ADR-HA admitted to a sample of French public hospitals was estimated at €1 020 549 (vs. €1 170 960). It could be estimated at €1.3 billion at the national level. In addition to the increase in the number of expensive drugs, the ageing population and polypharmacy, the economic impact of serious ADR-HA weighs heavily on healthcare spending. |
| Author | Jai, Taha Nerich, Virginie Valnet‐Rabier, Marie‐Blanche Laroche, Marie‐Laure Tarbouriech, Noémie |
| AuthorAffiliation | 2 UR 24134 (VieSanté‐Vieillissement, Fragilité, Prévention, e‐Santé), IFR OMEGA HEALTH Université de Limoges Limoges France 1 Regional Pharmacovigilance Centre of Limoges, Department of Pharmacology‐Toxicology and Pharmacovigilance CHU Limoges Limoges France 3 Pôle Pharmacie CHU Besançon Besançon France 4 Centre Régional de Pharmacovigilance et d'information sur le médicament CHU Besançon Besançon France 5 CHU Besançon, INSERM, EFS‐BFC, UMR 1098, Pôle Pharmacie Université de Franche‐Comté Besançon France |
| AuthorAffiliation_xml | – name: 4 Centre Régional de Pharmacovigilance et d'information sur le médicament CHU Besançon Besançon France – name: 5 CHU Besançon, INSERM, EFS‐BFC, UMR 1098, Pôle Pharmacie Université de Franche‐Comté Besançon France – name: 1 Regional Pharmacovigilance Centre of Limoges, Department of Pharmacology‐Toxicology and Pharmacovigilance CHU Limoges Limoges France – name: 3 Pôle Pharmacie CHU Besançon Besançon France – name: 2 UR 24134 (VieSanté‐Vieillissement, Fragilité, Prévention, e‐Santé), IFR OMEGA HEALTH Université de Limoges Limoges France |
| Author_xml | – sequence: 1 givenname: Marie‐Laure orcidid: 0000-0003-4344-0359 surname: Laroche fullname: Laroche, Marie‐Laure email: marie-laure.laroche@chu-limoges.fr organization: Université de Limoges – sequence: 2 givenname: Noémie surname: Tarbouriech fullname: Tarbouriech, Noémie organization: CHU Besançon – sequence: 3 givenname: Taha surname: Jai fullname: Jai, Taha organization: CHU Besançon – sequence: 4 givenname: Marie‐Blanche orcidid: 0000-0001-5737-5733 surname: Valnet‐Rabier fullname: Valnet‐Rabier, Marie‐Blanche organization: CHU Besançon – sequence: 5 givenname: Virginie orcidid: 0000-0002-0351-6040 surname: Nerich fullname: Nerich, Virginie organization: Université de Franche‐Comté |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39363642$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1UctuEzEUtVARTVsW_ADyEhZpfe0ZZ4YNSqMUKlUKaqdry-NHYzSxgz1TlB2fwDf2S-o0KQIE9sKy7nnY5xyhAx-8QegNkFPI66xV61PglPMXaASMl2MKtDxAI8IIH5e0hEN0lNJXQoABL1-hQ1YzznhBR8jOVfBh5RRuh6iNx8HiZUhr18sOS71yKbngE7Yh5uu9iclgHYc7HI1U_dPIeXwRpVfmA26WBl9Om-vFTTNtHn78nM8WOPWD3pygl1Z2ybzen8fo9mLezD6PrxafLmfTq7EqgG_fyq0urKw4qyrQlgJhGiwYXduaM2Yrm39jC5iUrSFKV0VL6xYIJZLaVgI7Rh93uuuhXRmtjO-j7MQ6upWMGxGkE39OvFuKu3AvACYTRmqWFd7tFWL4NpjUi5yBMl0nvQlDEgyAVmXedYa-_d3sl8tzuhlwtgOoGFKKxgqVc92mlr1dJ4CIbX8i9yee-suM938xnkX_hd2rf3ed2fwfKM5nX3aMR932qsw |
| CitedBy_id | crossref_primary_10_52881_gsbdergi_1743175 crossref_primary_10_1016_j_therap_2024_11_007 |
| Cites_doi | 10.1016/j.respe.2010.09.001 10.1007/s002280000260 10.1136/bmjopen‐2022‐062589 10.1080/14737167.2021.1981863 10.1007/s40264‐015‐0281‐0 10.1080/14740338.2018.1491547 10.1517/14656566.4.3.319 10.1111/fcp.12088 10.1111/bcp.12293 10.1016/j.therap.2021.12.007 10.1007/s00228‐023‐03552‐x 10.1016/j.jval.2012.05.007 10.1016/j.clinthera.2014.02.014 10.1111/bcp.12189 10.1111/bcp.15510 10.1186/s13613‐016‐0109‐9 10.1007/s002280050738 10.1007/s40264‐016‐0444‐7 10.2147/CIA.S304074 10.2165/00002018‐199920020‐00002 10.2165/11536800‐000000000‐00000 10.1016/j.jhealeco.2004.09.011 10.2165/00002018‐200022020‐00007 10.1001/jamanetworkopen.2021.47909 10.2147/CEOR.S115689 10.1007/s00228‐017‐2225‐3 |
| ContentType | Journal Article |
| Copyright | 2024 The Author(s). published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. 2024 The Author(s). British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. |
| Copyright_xml | – notice: 2024 The Author(s). published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. – notice: 2024 The Author(s). British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. |
| DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1111/bcp.16266 |
| DatabaseName | Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| DocumentTitleAlternate | Laroche et al |
| EISSN | 1365-2125 |
| EndPage | 450 |
| ExternalDocumentID | PMC11773093 39363642 10_1111_bcp_16266 BCP16266 |
| Genre | researchArticle Journal Article |
| GeographicLocations | France |
| GeographicLocations_xml | – name: France |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OC 23N 24P 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAMMB AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABOCM ABPVW ABQWH ABXGK ACAHQ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEFGJ AEGXH AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFEBI AFFPM AFGKR AFWVQ AFZJQ AGHNM AGXDD AGYGG AHBTC AIACR AIAGR AIDQK AIDYY AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB AOIJS ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD EMOBN EX3 F00 F01 F04 F5P FUBAC G-S G.N GODZA GX1 H.X HF~ HGLYW HYE HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LSO LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K ROL RX1 SUPJJ TEORI TR2 UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WVDHM WXI WXSBR X7M XG1 YFH YOC YUY ZGI ZXP ZZTAW ~IA ~WT AAYXX CITATION O8X CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c4166-526fd4fa863881df2103d1f1ed9f9633f8f251f4175be0cd84b29b1020a2fba13 |
| IEDL.DBID | DRFUL |
| ISICitedReferencesCount | 4 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001325665800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0306-5251 1365-2125 |
| IngestDate | Tue Nov 04 02:03:17 EST 2025 Fri Jul 11 08:37:04 EDT 2025 Mon Jul 21 05:58:01 EDT 2025 Sat Nov 29 03:17:18 EST 2025 Tue Nov 18 21:28:55 EST 2025 Wed Aug 20 07:26:43 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | adverse drug reactions hospitalization cost analysis pharmacovigilance observational study |
| Language | English |
| License | Attribution-NonCommercial-NoDerivs http://creativecommons.org/licenses/by-nc-nd/4.0 2024 The Author(s). British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4166-526fd4fa863881df2103d1f1ed9f9633f8f251f4175be0cd84b29b1020a2fba13 |
| Notes | The authors confirm that the Principal Investigator for this study is Professor Marie‐Laure Laroche. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0001-5737-5733 0000-0003-4344-0359 0000-0002-0351-6040 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbcp.16266 |
| PMID | 39363642 |
| PQID | 3112858589 |
| PQPubID | 23479 |
| PageCount | 12 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_11773093 proquest_miscellaneous_3112858589 pubmed_primary_39363642 crossref_citationtrail_10_1111_bcp_16266 crossref_primary_10_1111_bcp_16266 wiley_primary_10_1111_bcp_16266_BCP16266 |
| PublicationCentury | 2000 |
| PublicationDate | February 2025 |
| PublicationDateYYYYMMDD | 2025-02-01 |
| PublicationDate_xml | – month: 02 year: 2025 text: February 2025 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Hoboken |
| PublicationTitle | British journal of clinical pharmacology |
| PublicationTitleAlternate | Br J Clin Pharmacol |
| PublicationYear | 2025 |
| Publisher | John Wiley and Sons Inc |
| Publisher_xml | – name: John Wiley and Sons Inc |
| References | 2010; 33 2023; 79 2015; 38 2000; 22 2007 1999; 20 2011; 59 2012; 15 2022; 22 2016; 39 2005; 24 2017; 73 2016; 6 2021; 16 2018; 17 2023; 89 2015; 29 2013; 76 2000; 56 2022; 5 2022; 12 2003; 4 2014; 36 2016 2022; 77 2001; 56 2014; 78 2016; 8 e_1_2_11_10_1 e_1_2_11_32_1 e_1_2_11_31_1 e_1_2_11_30_1 e_1_2_11_13_1 e_1_2_11_12_1 e_1_2_11_11_1 e_1_2_11_33_1 e_1_2_11_7_1 e_1_2_11_29_1 e_1_2_11_6_1 Assurance Maladie (e_1_2_11_16_1) e_1_2_11_28_1 e_1_2_11_5_1 e_1_2_11_27_1 e_1_2_11_4_1 e_1_2_11_26_1 e_1_2_11_3_1 e_1_2_11_2_1 Yvonne M (e_1_2_11_20_1) 2007 Haute Autorité de Santé (e_1_2_11_14_1) World Health Organization (e_1_2_11_15_1) 2016 e_1_2_11_21_1 World Health Organization Collaborating Centres (e_1_2_11_18_1) e_1_2_11_25_1 e_1_2_11_24_1 e_1_2_11_9_1 e_1_2_11_23_1 e_1_2_11_8_1 e_1_2_11_22_1 e_1_2_11_17_1 e_1_2_11_19_1 |
| References_xml | – volume: 78 start-page: 202 issue: 2 year: 2014 end-page: 217 article-title: A systematic review of hospitalization resulting from medicine‐related problems in adult patients publication-title: Br J Clin Pharmacol – volume: 4 start-page: 319 issue: 3 year: 2003 end-page: 326 article-title: The cost of adverse drug reactions publication-title: Expert Opin Pharmacother – volume: 16 start-page: 767 year: 2021 end-page: 779 article-title: Economic evaluations of interventions to optimize medication use in older adults with polypharmacy and multimorbidity: a systematic review publication-title: Clin Interv Aging – volume: 39 start-page: 847 issue: 9 year: 2016 end-page: 857 article-title: Adverse‐drug‐reaction‐related hospitalisations in developed and developing countries: a review of prevalence and contributing factors publication-title: Drug Saf – volume: 89 start-page: 390 issue: 1 year: 2023 end-page: 400 article-title: Incidence and preventability of hospital admissions for adverse drug reactions in France: a prospective observational study (IATROSTAT) publication-title: Br J Clin Pharmacol – year: 2007 – volume: 12 issue: 9 year: 2022 article-title: Healthcare costs of adverse drug reactions and potentially inappropriate prescribing in older adults: a population‐based study publication-title: BMJ Open – volume: 22 start-page: 161 issue: 2 year: 2000 end-page: 168 article-title: Incidence and costs of adverse drug reactions during hospitalisation: computerised monitoring versus stimulated spontaneous reporting publication-title: Drug Saf – volume: 6 start-page: 9 issue: 1 year: 2016 article-title: An observational study of adult admissions to a medical ICU due to adverse drug events publication-title: Ann Intensive Care – volume: 38 start-page: 437 issue: 5 year: 2015 end-page: 453 article-title: Epidemiology of adverse drug reactions in Europe: a review of recent observational studies publication-title: Drug Saf – volume: 56 start-page: 935 issue: 12 year: 2001 end-page: 941 article-title: Analysis of the direct cost of adverse drug reactions in hospitalised patients publication-title: Eur J Clin Pharmacol – year: 2016 – volume: 20 start-page: 109 issue: 2 year: 1999 end-page: 117 article-title: The medical dictionary for regulatory activities (MedDRA) publication-title: Drug Saf – volume: 76 start-page: 56 issue: Suppl 1 year: 2013 end-page: 68 article-title: A new approach to identify, classify and count drug‐related events publication-title: Br J Clin Pharmacol – volume: 59 start-page: 53 issue: 1 year: 2011 end-page: 58 article-title: Critical analysis of French DRG based information system (PMSI) databases for the epidemiology of cancer: a longitudinal approach becomes possible publication-title: Rev Epidemiol Sante Publique – volume: 79 start-page: 1417 issue: 10 year: 2023 end-page: 1424 article-title: Costs associated with adverse drug reactions in an older population admitted to hospital: a prospective cohort study publication-title: Eur J Clin Pharmacol – volume: 36 start-page: 588 issue: 4 year: 2014 end-page: 592 article-title: Costs and length of stay of drug‐related hospital admissions in cancer patients publication-title: Clin Ther – volume: 24 start-page: 465 issue: 3 year: 2005 end-page: 488 article-title: Generalised modeling approaches to risk adjustment of skewed outcomes data publication-title: J Health Econ – volume: 56 start-page: 181 issue: 2 year: 2000 end-page: 186 article-title: Adverse drug reactions in a department of systemic diseases‐oriented internal medicine: prevalence, incidence, direct costs and avoidability publication-title: Eur J Clin Pharmacol – volume: 5 issue: 2 year: 2022 article-title: Estimated costs of severe adverse drug reactions resulting in hospitalization in the Veterans Health Administration publication-title: JAMA Netw Open – volume: 77 start-page: 291 issue: 3 year: 2022 end-page: 300 article-title: Epidemiology and economic burden of “serious” adverse drug reactions: real‐world evidence research based on pharmacovigilance data publication-title: Therapie – volume: 73 start-page: 759 issue: 6 year: 2017 end-page: 770 article-title: Hospital admissions due to adverse drug reactions in the elderly. A meta‐analysis publication-title: Eur J Clin Pharmacol – volume: 17 start-page: 681 issue: 7 year: 2018 end-page: 695 article-title: The economic burden of preventable adverse drug reactions: a systematic review of observational studies publication-title: Expert Opin Drug Saf – volume: 22 start-page: 627 issue: 4 year: 2022 end-page: 636 article-title: Prevalence and direct costs of potentially inappropriate prescriptions in France: a population‐based study publication-title: Expert Rev Pharmacoecon Outcomes Res – volume: 15 start-page: 868 issue: 6 year: 2012 end-page: 875 article-title: Costs of adverse drug events in German hospitals—a microcosting study publication-title: Value Health – volume: 29 start-page: 106 issue: 1 year: 2015 end-page: 111 article-title: Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study publication-title: Fundam Clin Pharmacol – volume: 33 start-page: 853 issue: 10 year: 2010 end-page: 864 article-title: Nature, occurrence and consequences of medication‐related adverse events during hospitalization publication-title: Drug Saf – volume: 8 start-page: 413 year: 2016 end-page: 426 article-title: A systematic review of observational studies evaluating costs of adverse drug reactions publication-title: Clinicoecon Outcomes Res – ident: e_1_2_11_32_1 doi: 10.1016/j.respe.2010.09.001 – volume-title: International statistical classification of diseases and related health problems, ICD‐10 year: 2016 ident: e_1_2_11_15_1 – ident: e_1_2_11_11_1 doi: 10.1007/s002280000260 – ident: e_1_2_11_25_1 doi: 10.1136/bmjopen‐2022‐062589 – ident: e_1_2_11_26_1 doi: 10.1080/14737167.2021.1981863 – ident: e_1_2_11_5_1 doi: 10.1007/s40264‐015‐0281‐0 – ident: e_1_2_11_9_1 doi: 10.1080/14740338.2018.1491547 – ident: e_1_2_11_10_1 doi: 10.1517/14656566.4.3.319 – ident: e_1_2_11_7_1 doi: 10.1111/fcp.12088 – ident: e_1_2_11_2_1 doi: 10.1111/bcp.12293 – ident: e_1_2_11_33_1 doi: 10.1016/j.therap.2021.12.007 – ident: e_1_2_11_23_1 doi: 10.1007/s00228‐023‐03552‐x – volume-title: Discrete multivariate analysis theory and practice year: 2007 ident: e_1_2_11_20_1 – ident: e_1_2_11_22_1 doi: 10.1016/j.jval.2012.05.007 – ident: e_1_2_11_28_1 doi: 10.1016/j.clinthera.2014.02.014 – volume-title: Les dépenses de santé en 2022—Résultats des comptes de la santé (Table 1, page 39)—Édition 2023 ident: e_1_2_11_21_1 – ident: e_1_2_11_30_1 doi: 10.1111/bcp.12189 – ident: e_1_2_11_6_1 doi: 10.1111/bcp.15510 – ident: e_1_2_11_13_1 doi: 10.1186/s13613‐016‐0109‐9 – volume-title: Classification commune des actes médicaux en ligne ident: e_1_2_11_16_1 – ident: e_1_2_11_12_1 doi: 10.1007/s002280050738 – ident: e_1_2_11_3_1 doi: 10.1007/s40264‐016‐0444‐7 – ident: e_1_2_11_27_1 doi: 10.2147/CIA.S304074 – ident: e_1_2_11_17_1 doi: 10.2165/00002018‐199920020‐00002 – volume-title: Guidelines for anatomical therapeutic chemical (ATC) classification system and defined daily dose (DDD) assignment ident: e_1_2_11_18_1 – ident: e_1_2_11_24_1 doi: 10.2165/11536800‐000000000‐00000 – volume-title: Choices in methods for economic evaluation ident: e_1_2_11_14_1 – ident: e_1_2_11_19_1 doi: 10.1016/j.jhealeco.2004.09.011 – ident: e_1_2_11_31_1 doi: 10.2165/00002018‐200022020‐00007 – ident: e_1_2_11_29_1 doi: 10.1001/jamanetworkopen.2021.47909 – ident: e_1_2_11_8_1 doi: 10.2147/CEOR.S115689 – ident: e_1_2_11_4_1 doi: 10.1007/s00228‐017‐2225‐3 |
| SSID | ssj0013165 |
| Score | 2.4728346 |
| Snippet | Aims
Hospitalizations for adverse drug reactions (ADR‐HA) have increased over the last decade, but the impact of ADR‐HA has rarely been evaluated. The aim of... Hospitalizations for adverse drug reactions (ADR-HA) have increased over the last decade, but the impact of ADR-HA has rarely been evaluated. The aim of this... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 439 |
| SubjectTerms | Adult adverse drug reactions Aged Aged, 80 and over cost analysis Cost of Illness Drug-Related Side Effects and Adverse Reactions - economics Drug-Related Side Effects and Adverse Reactions - epidemiology Female France - epidemiology hospitalization Hospitalization - economics Hospitalization - statistics & numerical data Humans Length of Stay - economics Male Middle Aged observational study Original Pharmacovigilance Retrospective Studies Young Adult |
| Title | Economic burden of hospital admissions for adverse drug reactions in France: The IATROSTAT‐ECO study |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbcp.16266 https://www.ncbi.nlm.nih.gov/pubmed/39363642 https://www.proquest.com/docview/3112858589 https://pubmed.ncbi.nlm.nih.gov/PMC11773093 |
| Volume | 91 |
| WOSCitedRecordID | wos001325665800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library - Journals customDbUrl: eissn: 1365-2125 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0013165 issn: 0306-5251 databaseCode: DRFUL dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEB71wYELlHd4VAtCFYca2bvbxKanEBqBVLVWcVFu1u56l0ZCThU3SL3xE_iN_SWdWT_SqCAhcbFsZeysxzP2Nzs73wC8Tbi2RaIHQT-UNpCRFoGmSRyFWzOIJDd-HvLb4eDoKJ5MknQN9ttamJofoptwI8_w72tycKWrG06uzfn7COF4fx02qagKI6_NTyfj08NlEiHynSQJFWO8tRc1xEK0kKc7efVzdAtj3l4qeRPC-m_Q-P5_jX4L7jXQkw1rW3kAa7Z8CDtpzV19ucuyZSlWtct2WLpktb58BK4tYWbaVz6wmWNnTdMRpgo0F5p3qxiCYDykxR6WFfPFd4ao1NdOVGxaMt_Hw36g_2JfhtnJ8ddsmF39-n0wOmae6fYxnI4PstHnoGnSEBjEcqTYviukUzE6MmJfhyGkKCIXoQU4dG7hYoeqdxJhirahKWKpeaIR1oSKO60i8QQ2yllpnwEzoUqUCUkEoyKzpyVXXBrKjAopDe_Bu_ZZ5aZhMKdGGj_yNpJBreZeqz1404me17QdfxJ63T7wHLVEmRJV2tmiygWiUEqYxkkPntYG0F1GJKIvcHw9iFdMoxMgwu7VX8rpmSfupgQ5ZZ7xRrxt_H1o-cdR6nee_7voC7jLqTmxX1L-EjYu5gv7Cu6YnxfTar4N61ymuB1M4u3GUa4BlS8Vgw |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEB6VggQXyrOE54JQxaGu7N1tYiMuIWrVipBaYFBv1u56l0ZCThU3SL3xE_iN_SXMrB9pVJCQuESJMok345nst_P4BuB1wrUtEj0I-qG0gYy0CDQFcRQ-mkEkufFxyK_jwWQSHx8n6Rq8a3than6ILuBGnuH_r8nBKSB9ycu1Od2JEI_3r8F1ibsSFfRxmS5zCJEfJEmgGI9bu1HDK0R1PN1HV3ejKxDzaqXkZQTrt6D9jf9b_B243UBPNqxt5S6s2fIebKU1d_X5NsuWrVjVNtti6ZLV-vw-uLaFmWnf-cBmjp00Q0eYKtBcKO5WMQTB-JKKPSwr5otvDFGp752o2LRkfo6HfUvXYofD7NPR52yYXfz8tTc6Yp7p9gF82d_LRgdBM6QhMIjlSLN9V0inYnRkxL4Oj5CiiFyEFuDQuYWLHereSYQp2oamiKXmiUZYEyrutIrEQ1gvZ6V9BMyEKlEmJBE8FZldLbni0lBmVEhpeA_etDcrNw2DOQ3S-J63JxnUau612oNXnehpTdvxJ6GX7R3PUUuUKVGlnS2qXCAKpYRpnPRgs7aA7mtEIvoC19eDeMU2OgEi7F59p5yeeOJuSpBT5hl_iDeOvy8tfz9K_ZPH_y76Am4eZB_H-fhw8uEJ3OI0qNiXlz-F9bP5wj6DG-bH2bSaP_d-8hsI3RYZ |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwEB4tC0JceD_K0yC04rBBie22CeJSylasWHUjCKu9RbZjs5VQWjVbpL3xE_iN_BJmnEe3WpCQuESJMkmcyUz82eP5BuBlwrUtEj0MBqG0gYy0CDRN4ijcmmEkufHzkEcHw-k0Pj5O0i142-bC1PwQ3YQbeYb_X5OD20Xhznm5NovXEeLxwSW4LPtD75ZcpusYQuQLSRIoxuFWP2p4hWgdT3fpZm90AWJeXCl5HsH6Lmhy4_8afxOuN9CTjWpbuQVbtrwNO2nNXX22y7J1Kla1y3ZYuma1PrsDrk1hZtpnPrC5YydN0RGmCjQXmnerGIJgPKTFHpYVy9VXhqjU505UbFYyX8fDvqFnsf1R9unwczbKfv34uTc-ZJ7p9i58mexl4w9BU6QhMIjlSLMDV0inYnRkxL4Oh5CiiFyEFuDQuYWLHereSYQp2oamiKXmiUZYEyrutIrEPdgu56V9AMyEKlEmJBEcFZm-llxxaSgyKqQ0vAev2o-Vm4bBnAppfMvbkQxqNfda7cGLTnRR03b8Seh5-8Vz1BJFSlRp56sqF4hCKWAaJz24X1tAdxuRiIHA9vUg3rCNToAIuzfPlLMTT9xNAXKKPOOLeOP4e9Pyd-PU7zz8d9FncDV9P8kP9qcfH8E1TnWK_eryx7B9ulzZJ3DFfD-dVcun3k1-A3UyFZQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Economic+burden+of+hospital+admissions+for+adverse+drug+reactions+in+France%3A+The+IATROSTAT%E2%80%90ECO+study&rft.jtitle=British+journal+of+clinical+pharmacology&rft.au=Laroche%2C+Marie%E2%80%90Laure&rft.au=Tarbouriech%2C+No%C3%A9mie&rft.au=Jai%2C+Taha&rft.au=Valnet%E2%80%90Rabier%2C+Marie%E2%80%90Blanche&rft.date=2025-02-01&rft.issn=0306-5251&rft.eissn=1365-2125&rft.volume=91&rft.issue=2&rft.spage=439&rft.epage=450&rft_id=info:doi/10.1111%2Fbcp.16266&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_bcp_16266 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0306-5251&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0306-5251&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0306-5251&client=summon |